PTPRJ

Across TCGA pan-cancer cohorts, PTPRJ Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PTPRJ data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PTPRJ Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTPRJ expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

LUSC, UCEC, and BLCA are the cancer types where PTPRJ Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.010	0.792	<.001	36	view →
UCEC	DFS	Median	All	0.922	0.612	.004	26	view →
BLCA	OS	Median	All	0.069	0.688	<.001	18	view →
STAD	DFS	Median	III,IV	0.192	0.597	.001	14	view →
OV	OS	Median	All	0.559	0.842	.014	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	II,III,IV	1.000	0.224	.023	6	view →
LGG	OS	Median	All	0.270	0.799	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PTPRJ–LUSC (DFS)

Open the LUSC breakdown →